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5Introductory note and acknowledgements
In-depth reviews of topical interest are published as Selected issues each year. These reports are based on information provided to the 
EMCDDA by the EU Member States, the candidate countries Croatia and Turkey, and Norway as part of the national reporting process.
The most recent Selected issues are:
• Cost and fi nancing of drug treatment services in Europe: an exploratory study;
• Treatment and care for older drug users;
• Problem amphetamine and methamphetamine use in Europe;
• Trends in injecting drug use in Europe;
• Drug off ences: sentencing and other outcomes;
All Selected issues (in English) and summaries (in up to 23 languages) are available on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/selected-issues
The EMCDDA would like to thank the following for their help in producing this Selected issue:
• the heads of Reitox national focal points, their staff  and the national experts on guideline development;
• the services within each Member State that collected the raw data;
• the members of the Management Board and the Scientifi c Committee of the EMCDDA;
• the Publications Offi  ce of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU Member States, 
Norway, the candidate countries and at the European Commission. Under the responsibility of their governments, the focal points are the national 
authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at:
http://www.emcdda.europa.eu/about/partners/reitox-network
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7The last two decades have witnessed an increase in the 
development of treatment guidelines in the European drugs 
fi eld. This has largely built on a body of evidence on the 
treatment of drug dependence that has developed since the 
1980s, alongside a growing interest in, and understanding 
of, the eff ectiveness of interventions. A range of tools 
became available to translate evidence into satisfactory and 
sustainable results, among them: guidelines and standards, 
education and training, implementation and assessment, 
monitoring, and accreditation systems based on quality 
standards.
The focus of this Selected issue is drug dependence 
treatment guidelines — one of the main measures used to 
improve and guarantee the quality of drug treatment 
provision. The focus on drug dependence treatment is timely 
and appropriate, as current estimates suggest that at least 
1.1 million people were treated for illicit drug use in the 
European Union, Croatia, Turkey and Norway during 
2009 (1). This is the consequence of a major expansion of 
specialised outpatient services during the last twenty years, 
with the signifi cant inclusion of primary healthcare, self-help 
groups, general mental health services, and outreach and 
low-threshold service providers. While more than half of 
clients received opioid substitution treatment, a substantial 
number received other forms of treatment for problems 
related to opioids, stimulants, cannabis and other illicit 
drugs. The main modalities used for the treatment of drug 
problems in Europe are opioid substitution, detoxifi cation 
and psychosocial interventions. Drug dependence treatment 
services are provided in a variety of settings: specialised 
treatment units (including outpatient and inpatient centres), 
mental health clinics and hospitals, units in prison, low-
threshold agencies and by offi  ce-based general 
practitioners. Particularly in western Europe, there appears 
to have been a gradual shift away from a view of drug 
dependence treatment as the responsibility of a few 
specialist disciplines providing intensive, short-term 
interventions towards a multidisciplinary, integrated and 
longer-term approach. Evidence suggests that continuous 
care and integrated treatment responses may be aided by 
the development and use of guidelines, care protocols and 
case management by all the relevant service providers 
(Haggerty et al., 2003). 
Introduction
This publication sets out to introduce the topic of treatment 
quality improvement by the development of guidelines (and 
other documents), and to provide an overview of the existing 
national guidelines for the treatment of drug dependence 
in Europe.
Sources of information
This Selected issue is based on the scientifi c literature and 
on data on drug dependence treatment guidelines in 
30 European countries (27 EU Member States, Croatia, 
Turkey, Norway), collected in three phases between 2008 
and 2010. 
A structured questionnaire completed by the Reitox national 
focal points was initially used to gather information about 
quality assurance and guidelines in the area of drug 
dependence treatment in Europe. National focal points also 
devoted a chapter in their national reports to a description 
of their countries’ guidelines and the context in which these 
were conceived. Results from both the questionnaires and 
the national reports were analysed and reported in a 
consultancy study. In addition, a meeting organised by the 
EMCDDA in February 2010 convened experts in the fi eld of 
guideline development from 30 European countries as part 
of the process for the development of the present Selected 
issue. 
Structure of this publication
The next section of this Selected issue introduces the issues 
relating to the methodology of guideline development and 
provides defi nitions of key terms. It then goes on to introduce 
the evidence on the impact of guidelines on drug 
dependence treatment services. Another section deals with 
the evolution of national treatment guidelines in Europe. This 
is followed by an examination of the wide range of 
European guidelines that are available on the EMCDDA 
Best practice portal, alongside lessons from national 
experiences of using the evidence base to construct 
guidelines, their implementation and plans for development. 
Finally, national guidelines on opioid substitution treatment 
are compared to those published by the World Health 
Organisation (WHO, 2009). 
(1)  Based on a range of diff erent sources, including the EMCDDA treatment demand indicator. See Table HSR-10 in the 2011 Statistical bulletin.
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how are they developed?
Guidelines usually contain a series of recommendations for 
practice that are based on a clear methodology, alongside 
an appraisal, synthesis and grading of the available 
evidence (Field and Lohr, 1992). Guidelines are primarily 
characterised by the validity of this methodological process 
(Brouwers et al., 2010), which should ensure that evidence 
from studies, carers’ experience and clients’ values and 
preferences are all taken into account.
Evidence-based guidelines are produced by convening 
multidisciplinary groups of experts who systematically assess 
the quality of the available evidence and classify the 
recommendations according to the level of supporting 
evidence. In general, evidence-based guidelines are 
published by independent organisations that are able to 
assemble experts who are free from confl icts of interest and 
who represent diff erent fi elds and professions. These groups 
generally involve as many stakeholders as necessary to 
ensure they appropriately address all the diff erent aspects of 
a question, including patients’ preferences and practical 
concerns arising from the experience of the carers. 
A number of tools have been developed to assess the quality 
dimensions in guidelines, the most recent being the ‘Appraisal of 
guidelines for research and evaluation’ (AGREE Collaboration, 
2003), which was created to address the issue of variability in 
guideline quality by assessing methodological rigour and 
transparency. The updated version, ‘AGREE II’ (AGREE Next Steps 
Consortium, 2009), is composed of six domains aimed at assessing 
whether or not the scope and purpose of the guidelines is clearly 
indicated; the stakeholders’ involvement is suffi  cient to represent the 
views of the intended users; the process of development was 
rigorous; the presentation and text are clear; and the guidelines are 
fi t for purpose and free from confl icts of interest. 
Setting the scene: national treatment guidelines
Glossary of terms
Accreditation is the process by which an institution delivering 
a service is independently assessed for quality against some 
pre-defi ned criteria. Accreditation requires a set of minimum 
standards, which are set by the accrediting body.
Benchmarking is the process of comparing service processes 
and performance metrics to best practices from other services. 
Dimensions typically measured are quality, time and cost. 
Clinical pathways are structured, multidisciplinary plans of 
care designed to support the implementation of clinical 
guidelines and protocols.
Guidance is a general term that covers documents such as guidelines 
and quality standards.
Guidelines are ‘statements that include recommendations intended to 
optimise patient care that are informed by a systematic review of 
evidence and an assessment of the benefi ts and harms of alternative 
care options’ (Institute of Medicine, 2011). They are designed to assist 
carers’ and clients’ decisions about appropriate interventions in 
specifi c circumstances.
Protocols, in general, are documents that specify the procedures to 
follow to perform some tasks, typically those used to conduct a study. 
Standards and quality standards are principles and sets of rules 
based on evidence (Brunsson and Jacobsson, 2000), used to 
implement the interventions recommended in guidelines. They can refer 
to content issues, processes, or to structural (formal) aspects of quality 
assurance, such as environment and staffi  ng composition. In some 
cases, standards are legally binding.
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The essential requirement for developing evidence-based guidelines 
is the availability of good quality studies addressing — and possibly 
answering — the pre-specifi ed questions that have been identifi ed by 
the group of experts working on the guidelines. When the evidence 
is scarce or contradictory and the clinical questions relatively 
focused and urgent, consensus conferences (Fink et al., 1984) are a 
possible option. During a consensus conference, a group of experts 
debate a series of presentations on available evidence and possible 
gaps. A jury composed of only some of the members of the group 
then vote on the fi nal recommendations. 
The RAND method of assessment of the appropriateness of 
medical technology (Brook et al., 1986) gathers consensus 
on the areas for which it is more diffi  cult to resolve 
dichotomous judgments; when it is not possible to collect all 
the information needed to tailor the interventions to ‘real 
world’ patients from the available studies; and, when the 
information from those studies needs to be integrated into 
existing multidisciplinary knowledge. The technology 
assessment methodology follows the same general steps as 
a review of the literature, but it is more concerned with the 
consequences of interventions in terms of the benefi ts and 
costs of healthcare and policy decisions (Liberati et al., 
1997). Therefore, a variety of stakeholders play a crucial 
role in the identifi cation of problems in the available data, the 
judgments and implications of studies’ fi ndings.
Are guidelines always needed? 
Some general conditions have been identifi ed as a prerequisite to 
developing guidelines. They are needed when there is proof that an 
intervention is heterogeneously provided to those receiving care, 
when there is controversy over the eff ectiveness of an intervention 
and when there is a need for integrating new evidence into a body 
of existing knowledge. If individuals with the same problems are 
receiving diff erent care depending on, for example, their doctor, 
health service, geographical location, gender, age or ethnicity, the 
development and/or adaptation of existing guidelines will make it 
more likely that all patients are cared for in the same manner (Woolf 
et al., 1999). If, on the other hand, it is clear that interventions are 
provided consistently to all patients, the impact is as intended and 
existing good practice is well-integrated into services’ routines, no 
guidelines are needed for improvement.
Grading of recommendations assessment, 
development and evaluation
Guidelines are composed of recommendations for action. 
Each of these recommendations should be based on some 
level of evidence from studies and should have an indication 
of its strength, which clarifi es how and when this is applicable 
to the target population. The level of evidence is determined 
by a synthesis of relevant studies’ design, number of 
participants studied and the number of studies sharing the 
same results. 
Although the level of evidence infl uences the strength of a 
recommendation, there are conditions under which, even 
where there is a lack of evidence from studies, the appointed 
group of experts may attribute a high strength to some 
recommendations. This is the case for some interventions, such 
as hydration for hospital patients or blankets to prevent heat 
loss in trauma patients, that are supported by practical 
experience evidence and do not need to be based on 
experimental evidence. Guidelines may therefore include a 
statement such as ‘we recommend that this intervention is 
off ered to most patients, even though there are no studies 
which prove or refute the eff ects, and this recommendation is 
based only on expert opinion’. Another example is where 
patients cannot be directly studied for ethical reasons (such as 
exposing newborn babies to diff erent drug therapies). In such 
cases, the recommendations can be based on the results of 
studies on other types of patients. In practical terms, this 
system, which separates level of evidence from strength of 
recommendations, produces two separate — but not completely 
independent — scores. 
In 2000, a collaboration was established of people interested in 
addressing the shortcomings of the grading systems used in guideline 
development, ‘The grading of recommendations assessment, 
development and evaluation’ (GRADE) working group (Guyatt et al., 
2011). Over the years, this group has developed and continuously 
updated a common, sensible and transparent approach to grading the 
quality of evidence and the strength of recommendations. The 
EMCDDA has offi  cially adopted this method to grade the level of 
evidence of the interventions that are summarised and published on 
the Best practice portal.
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Developing guidelines is a time-intensive and often 
expensive activity, and one that does not automatically lead 
to an improvement in the quality of treatment. There can be 
debate and controversy over the methods used and the 
choice of experts involved in their development. There can 
be disagreement as to whether guidelines should be specifi c 
and focused or broad and highly inclusive. The 
recommendations can be unfi t for purpose because they are 
too complex and diffi  cult to understand or, conversely, 
because they oversimplify the issues and do not use 
suffi  ciently technical language. 
Identifying and prioritising topics 
for guideline development
There are at least three approaches for prioritising the topics 
for guideline development, based on the epidemiological 
model, the request model and the economic model (Programma 
Nazionale Linee Guida, 2002).
The epidemiological model prioritises topics on the basis of 
observation of the incidence and prevalence of a health or 
drug use problem in the general population, the mortality 
caused by such a problem, importantly, the potential 
availability of eff ective interventions and the variation in 
practices that implement them. The main limitation of the 
epidemiological approach is that it focuses only on the 
occurrence of health or drug problems, neglecting to consider their 
social and contextual components.
The request model takes into consideration the perception of clients 
about a potential risk to which the health or drug treatment system 
should react. A typical example is the identifi cation of a new strain 
of seasonal infl uenza and the alarm this causes. In this case, the 
development of guidelines serves mainly to attract the attention of 
health carers to a potential risk to the general population. 
The third approach is based on an economic model. The 
rationale is that the allocation of resources corresponds to a 
subtraction of the same resources from other destinations. 
The model therefore considers the marginal costs of 
healthcare interventions. A typical example is those guidelines that 
specify in detail which patient characteristics ensure the success of a 
specifi c intervention, in order that it can be provided only to those 
patients who can benefi t from it.
Improvements in the evidence base leading to new insights may also 
be a reason to develop guidelines.
The impact of guidelines: the evidence
Guideline development has become a priority for many health 
service decision-makers, and it is a widely recognised instrument for 
quality assurance in the area of treatment provision (Lugtenberg et 
al., 2009). However, guidelines can be diverse in quality, and, if not 
based on evidence, they can even be counterproductive (Brouwers et 
al., 2010). The impact of guidelines on the improvement of the 
prognosis at patient level is not yet clear. In a recent debate 
promoted by the British Medical Journal about the eff ectiveness of 
guidelines (Grol, 2010), it was pointed out that to ensure clinical 
guidelines have an impact on actual care and practice, activities 
beyond the mere production and dissemination of guidelines should 
be instigated. In particular, performance measurement and quality 
improvement programmes should accompany the dissemination of 
guidelines. According to surveys, guidelines are applied to clinical 
practice in only 50–70% of day-to-day decisions, and the main 
reason given for not applying them is that they are of limited 
relevance to patients and healthcare staff  (Parchman et al., 2011).
Reported criticisms about guidelines include that they are concerned 
with only ‘ideal patients’, free from co-morbidities and complications, 
and that they are developed by single-discipline specialists, without 
taking into consideration the preferences of ‘real world’ patients 
(Krahn and Naglie, 2008).
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The fi rst guidelines in the medical fi eld were probably published in 
the United States in the early 1930s (American College of Surgeons, 
1931). A search in library catalogues (Weisz et al., 2007) found 25 
guidelines published between 1945 and 1959 and 35 between 
1960 and 1974. The majority of these were from the USA, with a 
small number from the United Kingdom.
In the mid-1940s, some refl ections on the need for basing 
the National Health Service (NHS) on scientifi c methods 
were undertaken in the United Kingdom and an important 
input came from Archibald Cochrane (1971) with his 
infl uential book ‘Eff ectiveness and effi  ciency. 
Random refl ections on health services’. Cochrane strongly 
emphasised the role of randomised controlled trials to 
‘open a new world of evaluation and control’ which would be 
‘the key to a rational health system’ (p. 11). 
In 1990, the Journal of the American Medical Association 
published a discussion on the need for developing clinical 
guidelines. It argued that clinical decision-making should be 
based on logical sequences of actions (Eddy, 1990). The 
plea for evidence-based medicine spread to the United 
Kingdom at the beginning of the 1990s, in parallel with the 
founding of the Cochrane Collaboration, an international 
organisation aimed at preparing, maintaining and 
disseminating systematic reviews of the eff ects of health 
interventions. In a short period of time, the availability of 
publications on syntheses of evidence-based medicine increased 
dramatically. 
The development of clinical guidelines spread to other 
European countries during the 1990s, and guidelines for the 
treatment of drug dependence followed the trend in the 
medical fi eld. The number of countries where national 
treatment guidelines were developed increased very rapidly 
after 1998. Today, nearly all the countries monitored by the 
EMCDDA (EU Member States, Croatia, Turkey, Norway) 
have such guidelines.
From voluntary to mandatory
The United Kingdom is an example of how clinical guidelines 
were initiated as a bottom-up and voluntary approach, in 
which groups of professionals developed their own documents 
to guide their activity. With the progressive adoption of 
Evolution of national treatment guidelines in Europe
evidence-based medicine, methods used to create guidelines 
became more complex and the activity passed to independent 
institutions created for the purpose (Berti and Grilli, 2003). 
Clinical guidelines began to become mandatory with the 
introduction of clinical governance, a general approach to 
monitoring and improving the quality, safety and 
eff ectiveness of clinical interventions (Harris and Taylor, 
2009). This approach included performance indicators and 
other instruments to control and monitor eff ective guideline 
application (Harrison and Smith, 2003). 
Typical content of guidelines
The guideline title may indicate the target group that is being 
considered, the professionals being addressed and/or the 
results that are expected, such as ’Guidance for the 
pharmacological management of substance misuse among 
young people in secure environments’ (National Treatment 
Agency, 2009). 
The aims and purpose are provided, along with the 
credentials of the authors and the panel of experts (including 
any declarations of confl icts of interest). Usually, a brief 
section introduces the epidemiology and description of the 
drug use or health problem being considered.
A list of recommendations is provided in the form of brief 
statements about what to do in some circumstances with some 
clients. For each recommendation, values are given that 
indicate the level of evidence that supports the 
recommendation and its strength (see box ‘Grading of 
recommendations assessment, development and evaluation’). 
A methods section describes in detail how the literature to 
support the recommendations was retrieved and assessed, 
how the information was extracted and how consensus among the 
panel of experts was reached. 
Appendices can be included and may contain, for example, 
further details of the studies that were examined, 
a questionnaire or checklist to apply the recommendations, 
and a literature list. The date of the search for literature 
and planned updates are also often included.
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regional partition of health government, which facilitates 
local approaches to guidance. In other cases, independent 
organisations provide treatment for the entire country, using 
their own guidelines.
Another example is the roll-out of substitution treatment across 
Europe, which took place mainly in the 1980s and 1990s, to be 
followed in the 2000s by the adoption by most countries of national 
guidelines (Figure 1).
The main motivations 
for developing guidelines
The main reason for investment in the development of drug 
addiction treatment guidelines in Europe was the link 
between injecting drug (mainly heroin) use and the associated risk 
of HIV and AIDS. This was addressed by a widespread introduction 
of pharmacological treatment for drug addiction and led to the need 
for recommendations for appropriate care. 
In some countries, an evidence-based approach to guideline 
development was adopted soon after drug addiction was 
considered a health condition to be treated with substitute 
pharmaceutical drugs. In Europe, the fi rst national treatment 
guidelines for drug addiction were issued in the United Kingdom 
and Ireland during the 1980s. The severity of the HIV/AIDS 
epidemic led southern European countries such as Spain, France, 
Italy and Portugal to adopt interventions that had proved eff ective 
elsewhere. These countries refl ected on their own experiences of the 
implementation of such interventions and draft treatment guidelines 
only after the emergency diminished. 
The increasing availability of guidelines
Over the last two decades, as discussed earlier, an 
increasing number of treatment guidelines have been 
produced (Institute of Medicine, 2011) along with other 
types of guidance that are aimed at assisting ‘practitioner 
and patient decisions about appropriate healthcare for 
specifi c clinical circumstances’ (Field and Lohr, 1992, p. 38). 
This development has been associated with other 
phenomena facing healthcare systems, especially an 
increase in the demand for care and a rise in the cost of 
providing it. For example, the ageing of the population, 
progress in medical treatment and, linked to that, new and 
more expensive technologies, have put considerable 
pressure on the healthcare system as a whole. This situation 
and the evidence of variations in service availability, delivery and 
quality have made quality a core issue within an increasingly 
competitive environment. Benchmarks and systematic assessments in 
the healthcare system concurred to stimulate the development and 
adoption of guidelines as a way of assuring quality in treatment 
provision.
This issue concerned all the health fi elds, including, more 
recently, drug addiction. While, until 2000, only six of the 30 
countries monitored by the EMCDDA had at least one 
national guideline for drug addiction treatment, by 2010, 
27 had such instruments, and the remaining countries used 
other means (regional guidelines, standards or accreditation 
systems) for quality development. So, not all European 
countries have adopted national treatment guidelines for 
drug addiction. In a few cases, this is simply due to the 
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Source: Reitox national focal points.
Figure 1: Availability of opioid substitution treatment and treatment guidelines in Europe — cumulative number of European countries
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A number of countries saw guideline development as part of 
a broader quality assurance strategy that includes the 
provision of education for healthcare workers, 
implementation of standards and certifi cation of quality. 
Advanced management tools for goal-setting, such as the 
‘balanced scorecard’ normally used in management (Kaplan 
and Norton, 2006), have also been adopted by some treatment 
centres. 
Government bodies stimulated the production of national guidelines 
as a means to reduce variations in treatment provision and clarify 
criteria for treatment access in the northern European countries. 
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As of June 2011, 143 national drug dependence treatment 
guidelines from 30 countries in Europe were collected and made 
available on the EMCDDA’s Best practice portal. The majority of 
these guidelines were published or updated after 2000. Guidelines 
are available in 22 European languages, with around a third in 
English (56), followed by German (10), Dutch (9), Czech (9), French 
(8) and Hungarian (8). 
Interventions and substances 
Just over a third of these 143 guidelines focus on opioid 
dependence (Figure 2). Specifi c attention is given to opioid 
substitution treatment with methadone or buprenorphine by 40% of 
the total number of guidelines and, in two cases, on the use of 
pharmaceutical heroin in the framework of medium to long-term 
treatment. Psychosocial interventions often accompany these 
pharmacological treatments: in some guidelines, there are detailed 
recommendations on these interventions.
A bookshelf of European drug dependence treatment guidelines 
Detoxifi cation from opioid dependence is the third most common 
topic for drug treatment guidelines across the European countries (2), 
and the medications suggested for this purpose are methadone, 
buprenorphine, lofexidine, alpha-2 adrenergic agonists (such as 
clonidine) and benzodiazepines for the control of withdrawal 
symptoms. 
Interventions aimed at the social reintegration of patients are also 
addressed by guidelines developed in just over a quarter the 
countries (3) and 10% of the guidelines focus on harm reduction, 
often as a broad umbrella strategy for several interventions.
Some guidelines address broad categories such as ‘drug 
dependence’ or ‘psychoactive substances’. Addressing drug 
dependence as a whole without substance specifi cation is more 
common in the guidelines on psychosocial interventions, social work, 
social reintegration and community care. Approximately 10% of 
guidelines have alcohol as one of their major topics and slightly 
fewer address (misuse of) medicines, for example sedatives.
Although the majority of guidelines focus on opioids (Figure 3), 
some address issues related to other substances: Germany and the 
Netherlands, for example, devote specifi c guidelines to cannabis-
related problems; Germany and Hungary have guidelines for the 
treatment of amphetamine-related disorders; and the guidelines from 
Germany and France include strategies for the care of cocaine 
users.
Guidelines for psychosocial interventions: a toolkit
A psychosocial toolkit recently published by the British 
Psychological Association and the National Treatment Agency 
for Substance Misuse, in which the key competences for each 
psychosocial intervention are presented and discussed. The 
toolkit, which is aimed at practitioners working with adult drug 
service users (with or without co-morbid mental health 
problems), is complemented by a specimen training curriculum 
for each intervention, protocols for implementation, audit 
criteria and adherence measures (Pilling et al., 2010).
(2)  In guidelines from Belgium, Bulgaria, Czech Republic, Denmark, Germany, Estonia, Ireland, Latvia, Hungary, Netherlands, Austria, United Kingdom.
(3)  Bulgaria, Czech Republic, Germany, Estonia, Hungary, Portugal, Slovenia, United Kingdom.
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NB:  Categories are not mutually exclusive.
Source: Reitox national focal points.
Figure 2: Number of guidelines by type of intervention 
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overall, the type of client the guidelines address varies considerably 
and includes prisoners, women, young drug users and dependent 
drug users with co-occurring disorders. In 2009, an EMCDDA 
consultation study asked for specifi c guidelines dealing with 
migrants and sex workers, but none were found in the guidelines 
examined.
Around a quarter of the countries have developed guidelines about 
treatment in prison or other secure settings. For example, the Czech 
Republic has published a set of standards for prison drug services 
that are provided by external organisations; 15 guidelines, from 
almost a third of the countries, addressed people with co-occurring 
disorders besides drug use; and one third of the European countries 
have developed guidelines specifi cally tailored to the 
treatment needs of young drug users and dependent drug 
users with co-occurring disorders.
Guidelines on treatment for cocaine dependence 
The Haut Autorité de Santé in France recently published 
guidelines to deal with cocaine use. They are aimed at 
identifying and recruiting problem cocaine users into 
treatment, providing information on the consumption of 
cocaine and on how to reach specifi c client groups, such as 
pregnant women, adolescents and young people, and persons 
with risky sexual behaviours. Treatment pathways for cocaine 
users, and diagnostic criteria for dependence are presented, 
and the possible complications and how to treat them are 
discussed. The guidelines include strategies to reduce the risks 
associated with cocaine use, and a range of psychosocial 
interventions are presented, along with information on the 
pharmacological treatment for withdrawal symptoms 
(Haute Autorité de Santé, 2010).
Target population and client groups
The target population is the group of people who are expected to 
read and implement the guidelines in their daily activity — primarily 
service providers and professionals. However, only just over one 
quarter of countries address healthcare planners in their 
guidelines (4): overall, the results of the present analysis reveal that 
drug addiction treatment guidelines in Europe are primarily intended 
to be of practical use for individuals and organisations directly 
involved in providing care for drug users.
Each country has several sets of guidelines and in terms of clients 
(or, as defi ned in the medical literature, ‘case defi nitions’), they all 
have at least one set that addresses a specifi c client group. Two 
thirds of countries refer to long-term dependent drug users, but 
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Figure 3: Number of guidelines by type of substance
(4)  Bulgaria, Czech Republic, Denmark, Ireland, Netherlands, Austria, Sweden, United Kingdom.
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This section describes how the European national treatment 
guidelines are developed at national level, the level of 
evidence they use and countries’ implementation strategies, 
including how the consultation process with diff erent 
stakeholders is managed. 
In their guidelines, around a third of countries referred to the 
existence of standardised guideline drafting procedures or 
to other, more general arrangements, such as laws on the 
guideline drafting process (Latvia, Lithuania, Hungary) or 
offi  cial quality standards that are in place at national level. 
Over one third of the countries reported using international 
treatment guidelines, such as those from the World Health 
Organisation or those published in other countries. Some of these 
countries adapted others’ guidelines to their national context, while 
others used them as a base to build upon (5). 
The majority of the countries explicitly stated the main 
objective for drafting treatment guidelines at national level. 
The most common objectives were to harmonise treatment 
services and/or to improve the quality of treatment. Other 
objectives included the need to create standards for 
accreditation/certifi cation procedures, to improve the 
cost-eff ectiveness of treatment services and to monitor 
treatment quality.
It was generally acknowledged that evidence should be the 
basis for treatment guidelines, and most countries reported a 
process, or combination of processes, to ensure that the 
available evidence was included in their guidelines. Ten 
countries explicitly mentioned that the available evidence 
formed the basis for their guidelines, and the Netherlands reported 
on specifi c trials that were conducted to create the necessary 
evidence base for future guidelines. Most countries’ guidelines were 
issued for only a fi xed period of time, thus enforcing regular 
updating. Other evidence-related features of guidelines included 
systematic scientifi c reviews, expert consensus and the importance of 
experience and good practice. Six countries stated that their 
guidelines, once drafted, were reviewed by a panel of independent
Developing national guidelines: lessons from experience 
experts before being formally adopted. In the United Kingdom, one 
of the tasks of this independent panel was to make sure that all 
contributions from all relevant stakeholders were considered by the 
working group drafting the guidelines. 
However, only just over one quarter of the countries provided 
detailed information on the need to establish clear links between the 
recommendations and the evidence available and only fi ve of these 
indicated that recommendations need to be explicitly linked to the 
evidence according to its reliability or acknowledged scientifi c value.
As for the stakeholders involved in drafting guidelines, the situation 
varied greatly among European countries. In most, health authorities 
were the main stakeholder involved, usually through the national 
departments of health. Health authorities initiated the process and 
were responsible for developing the guidelines by appointing 
working groups, and/or by granting the fi nal approval of the 
guidelines. However, in some countries, these responsibilities lay 
with independent professional organisations, such as medical 
councils, national government bodies or independent scientifi c 
associations; in such cases, representatives of national health 
authorities had a less prominent role in guideline development, as 
regular working group members or observers. 
In the Netherlands and the United Kingdom only, patient/carer 
organisations have a formal role in the development process, 
although in many other countries they are included at a later stage 
or given the opportunity to comment on draft guidelines. The other 
stakeholders involved are mainly healthcare professionals, 
psychiatrists and psychologists, but universities and quality experts 
are also mentioned as contributors to the fi nal output of the guideline 
working groups.
Five countries have a mandatory consultation procedure during the 
drafting of treatment guidelines. In the Czech Republic, France and 
Sweden, this is conducted among the relevant professional or expert 
communities; in Portugal it involves the central and local 
governmental services that deliver treatment; and, in the United 
Kingdom, it involves an extensive group of stakeholders and at least 
one public consultation before the guidelines are formally adopted.
(5)  Adapting guidelines (ADAPTE Collaboration, 2011) to a specifi c context requires that a local group of stakeholders identify specifi c questions, searching 
for, retrieving and assessing available guidelines, and preparing the draft adapted guideline.
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real diff erence is made when there is a valid implementation 
programme. However, the implementation process is not always 
straightforward, and changes and innovations can meet resistance. 
The main barriers to the implementation of guidelines can be related 
to social, organisational and economic context, individual reactions 
by professionals, and sometimes resistance at client level (Grol, 
2010). 
Not all the countries reported their strategies to implement national 
treatment guidelines, and those that did reveal varying experiences. 
Most countries applied a bundle of measures during the 
implementation of their guidelines. Some examples follow, but these 
should not be taken as the only implementation strategies of the 
countries mentioned.
An approach followed by Belgium, the Czech Republic, Cyprus, 
Luxembourg and Norway can be described as tackling the attitude 
of professionals and the social and organisational context of drug 
treatment services. Through studies aimed at identifying possible 
barriers and ways forward, these countries created implementation 
manuals and standards. In Denmark, the implementation of 
guidelines was assessed using a set of indicators for quality 
assurance. In Ireland, the tasks of the Methadone Prescribing 
Implementation Committee include overseeing guideline 
implementation. 
Another vehicle for ensuring adherence to guidelines is by involving 
key professionals in the promotion of change (Grol and Wensing, 
2004). This seems to be the main strategy adopted by Finland, 
Germany, Latvia and Slovenia, where the medical associations or 
the coordinators of treatment centres prepared the guidelines and 
disseminated them among their members. 
Continuous learning in terms of guidelines and their 
implementation is a shared feature across Europe. For 
instance, in the Baltic States, the guidelines are included in 
the training of psychiatrists and in ongoing training courses 
for medical practitioners. Some countries, including Hungary 
and Austria, created a legal framework for service providers 
to implement the guidelines, and these are made available 
by the relevant ministries in their offi  cial publications and on 
their websites.
In the Netherlands, one of the leading countries in research 
on implementation, an evaluation instrument for physical 
and mental health (KRIE) was created that assesses the 
‘implementability’ of guidelines (Fleuren et al., 2009). A series of 
studies (Sinnema et al., 2009; Smolders et al., 2006) came to the 
conclusion that after having invested in the development of 
guidelines, future eff orts should be directed towards an increased 
implementation rate, particularly by the use of computer software 
programmes, for boosting the effi  ciency of care processes and for 
advice, evaluation and feedback. Investment in interactive 
workshops also proved eff ective in terms of implementation. 
A project for European minimum quality standards 
The EQUS study, commissioned by the European Commission (1), 
convened a number of experts and stakeholders from all over Europe 
and beyond, in order to propose lists of minimum standards based on 
evidence and consensus. The results are expected to be available by 
the end of 2011, and will be used by the Commission to draft a 
proposal to the Council by 2013 (2). 
(1)  ‘Development of an EU framework for minimum quality standards and 
benchmarks in drug demand reduction’ (available at 
http:/ec.europa.eu/home-aff airs/tenders/2009/312290/tender_en.pdf).
(2)  For further information, see the EMCDDA Best practice portal (http://www.
emcdda.europa.eu/themes/best-practice/standards).
Five countries refer to follow-up approaches after the implementation 
of national treatment guidelines, which can provide information for 
the updating process and the development of new guidelines. The 
follow-up work comprises general feedback on implementation 
(Greece), surveys of general practitioners (Ireland) or municipalities 
(United Kingdom) and perceptions of guidelines among professionals 
during the pilot phase of their implementation (Czech Republic). The 
Netherlands has a dedicated follow-up programme in place to help 
improve the redrafting process.
The evidence base for guidelines
The 20 national guidelines on opioid substitution treatment that were 
available on the EMCDDA’s Best practice portal in April 2011 were 
examined to see whether bibliographic references to specifi c studies 
formed the evidence base for the recommendations. 
Surprisingly, a number of the selected guidelines did not even 
provide a bibliography or reference section. However, the 
remainder show consideration of the recent evidence base. For 
example, the guidelines from Latvia cite a considerable number of 
studies in the bibliography (20 studies in 26 references), 70% of 
them published in the fi ve years before the guidelines’ publication. 
Guidelines from Belgium, the Netherlands and the United Kingdom 
also show that the evidence base for recommendations consists of a 
high number of studies.
Across the guidelines on opioid substitution treatment, the highest 
proportion of references is to randomised control trials and to the 
Cochrane library as a general resource for evidence on treatment. 
This is especially the case in the guidelines from Germany and the 
United Kingdom.
Implementation: 
what helps and what hinders?
Across Europe, it has been recognised that developing guidelines is 
an important step towards improvement of practice, although the 
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Plans for developing guidelines for 
treatment of drug dependence in Europe
Overall, there is a sense of coherence in the identifi cation of tools and 
topics for the future. The countries appear to follow a common 
pathway when developing guidelines, starting with the medical 
treatment of opioid dependence. Once guidelines for this treatment 
provision are produced, they focus on more detailed issues that the 
guidelines should address (such as subgroup populations), as well as 
a more sophisticated analysis of impact and hypotheses for further 
development. 
For most countries, updating and/or redrafting guidelines is an 
ongoing process. Hungary, for example, adopted a statement that 
healthcare guidelines are to be reviewed every two years. A SWOT 
(strengths, weaknesses, opportunities and threats) analysis of the last 
15 years of activities has been undertaken in the Czech Republic. It 
concludes that in spite of the advances made in standards 
and quality accreditation, more eff orts could be put into 
guideline development. The tools identifi ed for future 
development include manuals targeted at practitioners, 
focusing on how to apply the recommendations from evidence-
based guidelines. Belgium is planning to use these after their current 
pilot study in their substance use services.
Countries have chosen to focus new guideline development in a 
range of diff erent areas. Non-medical treatment with psychosocial 
therapy and rehabilitation has been identifi ed as a topic for further 
development in Germany. In Estonia, the quality of methadone 
substitution treatment has been identifi ed as a topic for further 
development, in collaboration with the United Nations Offi  ce on 
Drugs and Crime (UNODC). In Portugal, the most recent guidelines 
dealt with harm and risk reduction in private/public partnerships. In 
the United Kingdom, the next update will focus on detoxifi cation and 
psychosocial interventions, and new guidelines will consider 
pregnancy and the complex social factors surrounding drug use.
An important refl ection on the need for focused (rather than 
general) guidelines addressing subgroup populations is underway 
in the Netherlands, where future activities are envisaged as the 
adaptation of existing guidelines to the needs of specifi c groups of 
patients. A platform for evidence-based guideline development 
(EBRO) has been created and an open discussion has been 
launched on the drawbacks arising from an excessive proliferation 
of tools for quality, which risks shifting the attention from the patients 
towards the actual management and production of guidance. In 
Sweden, the need for more involvement of patients in the quality 
process was identifi ed, and also that this can only be achieved if 
the health and social care system perceives itself as a learning 
organisation with fl exible borders.
Strategies for effective guideline implementation
Grol and Wensing (2004) list the following strategies to overcome 
obstacles to change in healthcare services:
1.  Innovation: a proposed innovation has to be attractive, feasible and 
likely to improve practice.
2.  Individual professionals: awareness and motivation to change 
should be promoted.
3.  Patient level: compliance should be promoted.
4.  Social context: the culture of the professional network 
and the opinions of colleagues and leadership have 
to be changed.
5.  Organisational context: organisational processes to 
ensure the necessary capacity, resources and staff  must 
be in place.
6.  Economic and political context: fi nancial arrangements, regulations 
and policies need to be created.
A milestone project for assessment of implementation is ‘Scoring 
results’, which adopted fi ve phases for a successful process: 
orientation, insight, acceptance, change and maintenance (Grol and 
Wensing, 2004). The adherence to implementation is measured as a 
percentage of 
organisations that routinely applied a set of six guidelines. 
This gave positive results for two guidelines on drug 
treatment: methadone maintenance scored 90% 
and detoxifi cation in inpatient and outpatient settings 
scored 64%. 
A recent study conducted in the United Kingdom (Luty et al., 
2010) showed that there was a huge investment in the 
implementation of guidelines. The National Institute for 
Health and Clinical Excellence (NICE) has produced a 
range of ‘how to’ guides to help with the implementation of 
their guidance at a local level. An interesting initiative for 
dissemination is the ‘Shared learning database’ that enables 
organisations that have implemented NICE guidance to 
share tips, ideas and examples of their implementation 
process. The UK is also trialling new approaches to 
payment-by-results to test whether paying on the basis of the 
outcomes achieved can further incentivise the delivery of 
recovery for those who are dependent on drugs and/or 
alcohol. Eight local areas will be testing the approach over 
two years and a formal evaluation is being put in place (6).
(6) Further information can be found at http://www.dh.gov.uk/health/2011/07/drug-and-alcohol-recovery/ 
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After an open discussion about the quality of its own guidelines, the 
World Health Organisation (WHO) put procedures in place for 
developing transparent, evidence-based guidelines, adopting 
standard methods for the synthesis of the evidence and the grading 
of recommendations (Barbui et al., 2010). Using these methods, 
‘Guidelines for psychosocially assisted pharmacological treatment 
of opioid dependence’ was published (WHO, 2009). The WHO 
guidelines contain a series of recommendations based on evidence 
from systematic reviews and meta-analyses, along with evidence 
from other sources, technical considerations, resource implications 
and the risks and benefi ts of diff erent alternatives. The strength of 
each recommendation is based on consideration of the eff ectiveness 
of the intervention, the level of the evidence to support it and the 
resource implications.
The WHO guidelines are grouped according to their target 
audiences: recommendations for health systems at national and 
sub-national levels; for treatment programmes; and for treatment of 
the individual patients. For the purpose of this section, the 
15 recommendations for the treatment of the individual opioid 
dependent user were selected and compared with some of the 
recommendations included in European countries’ national 
guidelines for the treatment of opioid dependence. 
On the EMCDDA’s Best practice portal in July 2011, 57 of 
the national guidelines from 24 countries contained 
recommendations on opioid substitution treatment. Only 
18 of these were published after the WHO guidelines, so 
the following discussion should not be interpreted as an 
assessment of the impact of the 2009 WHO guidelines, but 
rather as a preliminary overview of the convergence or 
otherwise of some of the recommendations from across 
Europe. 
In terms of choice of pharmacological treatment for opioid 
dependence, the WHO guidelines recommend that 
clinicians off er detoxifi cation (withdrawal) and substitution 
treatment (with agonist medications such as methadone or 
buprenorphine). These two key WHO recommendations are 
refl ected in just over a third of the selected 57 sets of 
guidelines. In addition, there are some national guidelines for the 
treatment of opioid dependence which contain recommendations 
that are not completely in line with the WHO advice, for example 
National and WHO guidelines for the treatment of opioid dependence: 
differences and similarities 
suggesting only provision of drug free treatment. A number of other 
guidelines do not address this issue. 
There are diff erences concerning the choice of methadone 
or buprenorphine to treat those dependent on opioids. Some 
countries do not indicate a preference: in two of them, 
buprenorphine is not (or has only recently been) available, 
whereas in a number of countries, buprenorphine is the fi rst 
choice for opioid substitution treatment. The guidelines 
specify the dosage that should be given in the induction 
period (at the beginning of treatment). Some of the countries 
follow the same conventions, while others do not or leave 
the decision to the relevant medical doctors. Almost all the 
countries’ guidelines agree on the need for direct 
supervision of methadone and buprenorphine doses in the 
early phase of treatment, and specify conditions under 
which take-away doses can be given to treatment clients. 
Among the countries that address pregnant drug users in 
their guidelines, there is some agreement that they should be 
off ered opioid agonist maintenance, and there is a 
preference for methadone. It is worth noting, however, that 
there is some new evidence to suggest buprenorphine may 
also be a valid option for this group (Jones et al., 2010).
Management of opioid withdrawal with opioid agonists or alpha-2 
adrenergic agonists is recommended in the majority of the European 
guidelines, but there are diff erences concerning the use of minimal 
or heavy sedation. In some cases, the options are only listed, without 
an indication of preference. However, the WHO guidelines warn 
about the risks of this intervention: they recommend that the 
combination of minimal sedation with opioid antagonists 
should not be used routinely, and heavy sedation with 
opioid antagonists should never be used. For clients not 
undergoing maintenance treatment, the WHO guidelines 
recommend the use of antagonist drugs such as naltrexone 
(which blocks the eff ect of heroin in the user’s body) after 
detoxifi cation. This recommendation appears in eight 
countries’ guidelines. Six do not mention this option and three have 
slightly diff erent recommendations, mainly due to naltrexone being 
unavailable in the countries they cover. 
Almost without exception, the national guidelines concur with the 
WHO recommendations that psychosocial support should be 
routinely off ered alongside pharmacological treatment during 
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long-term treatment and detoxifi cation programmes for opioid 
dependence. 
In summary, despite the diff erences in the rationale for, and 
the process of developing guidelines in Europe, in the 
subsample of 57 sets of guidelines on psychologically 
assisted pharmacological treatment for opioid dependence 
examined for this Selected issue, there is much agreement 
regarding the general aspects of this treatment — provision 
of detoxifi cation, maintenance, supervision during the 
induction period, regulation of take-away doses, and 
psychological assistance and individual assessment during 
treatment. And, while there are signs of convergence 
regarding the WHO guidelines, only one third of the 
guidelines contain the two key recommendations on 
detoxifi cation and opioid substitution treatment. Moreover, 
there is much diversity in terms of clinical recommendations 
concerning the dosages and combinations of pharmaceutical drugs 
to be used during treatment.
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This Selected issue has identifi ed a major increase in the availability 
of guidelines for treating drug use and dependence across Europe. 
Overall, the 143 sets of guidelines from across Europe reveal a 
commitment to improving the quality of treatment, helping 
practitioners to make more informed choices and, signifi cantly, 
putting the clients at the centre of the therapeutic process. Currently, 
guidelines are available in 24 European languages, and when 
similarities and diff erences are considered against the varied 
historical and cultural backgrounds that characterise Europe, the 
value of the eff ort made to reach a common strategy and to share 
best practice becomes clear. 
There is a relationship between the year a country 
introduced opioid substitution treatment and the year in 
which the production of clinical guidelines for the treatment 
of opioid dependence started. The number of drug users receiving 
substitution treatment in Europe has increased almost 10-fold since 
the beginning of the 1990s (EMCDDA, 2010), which is the period in 
which guidelines were increasingly produced. The majority of the 
existing guidelines focus on the pharmacological treatment of heroin 
dependence. This seems logical, as guidelines originated in 
the medical discipline, in which experimental studies that 
inform clinical recommendations are also conducted. 
However, there are numerous examples of guidelines that 
also cover other interventions, drugs other than heroin and 
address the treatment of groups of drug users other than 
those dependent on heroin. A comparison between the 
national guidelines on opioid substitution treatment and the 
evidence-based recommendations provided by the World 
Health Organisation reveal considerable convergence, with 
the exceptions of options for the fi rst choice of 
pharmaceutical drug to treat dependence and the level of 
detail in recommendations on dosages.
The scientifi c literature underlines that new treatment guidelines are 
not always needed and that adaptation of pre-existing evidence-
Conclusions 
based guidelines may be a feasible alternative. In the context of an 
increasingly shared eff ort to improve quality, a consensus around 
minimal standards appears to be an option to try to achieve 
homogeneity of intervention provision, while allowing for national 
choices and diff erences. It is important to note that guidelines are 
developed and published at diff erent levels: local, national, EU and 
global. High quality evidence is by defi nition valid and exportable 
to any context, but adaptation at each level is nonetheless essential 
for successful implementation. The adaptation process at local level, 
for example, needs to take into account the specifi c environment, 
local organisations, culture, resources and clients’ preferences 
(Graham et al., 2002). Guideline implementation strategies are 
recognised as key to improving the quality of treatment and to 
changing practice. The European countries reporting on these depict 
a range of well thought-out strategies that are worth describing in 
more detail than the present publication allows. 
The present overview cannot provide a full picture of the wealth of 
experiences and strategies to improve treatment quality at national 
level in Europe. Rather, it can be considered as an introduction to the 
guidelines from the 30 participating European countries published 
on the EMCDDA’s Best practice portal. The EMCDDA will continue 
to collect national guidelines and make them available, 
thanks to the invaluable collaboration of the network of 
national focal points and their nominated experts.
Monitoring and reporting and the strategies for promoting 
best practice and ensuring treatment quality at national level 
is a long-term activity, and one that requires considerable 
investment and networking of key stakeholders. The present 
publication is a fi rst step. Despite its limitations, it is 
necessary to continue on this track to disseminate 
information on the valuable national eff orts, creativity 
and results.
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is 
one of the European Union’s decentralised agencies. Established in 1993 and 
based in Lisbon, it is the central source of comprehensive information on drugs 
and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, reliable 
and comparable information on drugs and drug addiction. In doing so, it 
provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide range 
of audiences including policymakers and their advisors; professionals and 
researchers working in the fi eld of drugs; and, more broadly, the media and 
general public.
